Business Wire

PENTAX Medical Launches OPTIVISTA-EPK-i7010 Video Processor

Del

PENTAX Medical launches a world first, the OPTIVISTA EPK-i7010 Video Processor, featuring both digital and optical enhancements, in the European, Middle Eastern & African (EMEA) markets. This unique enhancement combination provides detailed information for more accurate in vivo diagnosis through improved vessel and mucosal pattern characterization.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160510005811/en/

The new OPTIVISTA EPK-i7010 video processor uniquely features both digital and optical enhancements  ...

The new OPTIVISTA EPK-i7010 video processor uniquely features both digital and optical enhancements for more accurate in vivo diagnosis. For a high resolution image, please contact sarahp@alto-marketing.com (Photo: Business Wire)

The introduction of OPTIVISTA offers physicians both digital (i-scan Surface and Tone Enhancements) and Optical Enhancement (i-scan OE), with the new optical filter producing bandwidth-limiting light. When combined with image enhancement processing technology i-scan OE clearly displays the surface structures of blood vessels, glandular ducts and mucosal membrane in higher contrasts than white light. This unique combination with the proven digital i-scan technology, in one video processor, provides an enhanced view of the mucosal structures and vascular patterns, supporting early detection, demarcation and characterization. Physicians can switch seamlessly in real time amongst HD+ white light and three i-scan modes which includes i-scan OE to view multiple aspects of tissue structure.

PENTAX Medical’s new OPTIVISTA EPK-i7010 video processor, together with its latest i10 HD+ endoscopes series, or with its MagniView, optical zoom endoscopes, provides market leading image quality. Perfectly suited to routine procedures or complex interventions, the OPTIVISTA is designed to support the optimal clinical outcome.

Dr Silvia Sanduleanu, Maastricht UMC+, The Netherlands, who has been involved in early studies with OPTIVISTA said, “Contrast enhancement using i-scan OE highlights the epithelial mucosal surface pattern and especially the vascular pattern in detail. i-scan OE facilitates detection and in vivo diagnosis of lower gastrointestinal tract pathology enabling targeted endotherapy.”

In addition to improved diagnosis, OPTIVISTA is a powerful teaching platform. TwinMode is useful in teaching the appropriate interpretation of image enhanced endoscopy, providing simultaneous comparison of side by side endoscopic images. The simultaneous comparison of enhanced clinical images is particularly useful in demonstrating the appropriate characterization of lesions.

Also included with the OPTIVISTA is the ability to perform video recording, enabling the capture of HD+ video files onto a USB storage device. Audio recording for video is captured through an external microphone. The new, intuitive touch screen controls allow for simple and efficient operation. For optimum image collection, the OPTIVISTA incorporates freeze scan technology which automatically selects the sharpest picture for users’ records. By integrating the video and audio capture functionality there is no requirement for further recording devices or software.

Rainer Burkard, President EMEA of PENTAX Medical commented: “This is just one of a series of exciting product launches for PENTAX Medical this year. We are looking to increase our support to consultants across GI, ENT and bronchoscopy by adding to our product portfolio over the coming months. This is a proud moment for us as a business, OPTIVISTA will have a marked effect on the diagnosis possibilities for consultants. Working with our other technologies we are in a strong position to support the entire clinical pathway, from initial identification through to therapy.”

About PENTAX Medical

PENTAX Medical is a division of HOYA Group. Its mission is to improve the standard of patient care and quality of healthcare delivery by providing the best endoscopic products and services with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION, and SIMPLICITY. Through leading edge R&D and manufacturing, PENTAX Medical provides endoscopic imaging devices and solutions to the global medical community. Headquartered in Japan, PENTAX Medical has a worldwide focus and presence with R&D, regional sales, service, and in-country facilities around the globe. For more information, please visit: www.pentaxmedical.com.

Contact information

PENTAX Europe GmbH
Sangeeta Gehlot-Vadher
EMEA PR Manager
T: +44 (0)1753 792 733
F: +44 (0)1753 792 794
E: sangeeta.gehlot@pentaxmedical.com
W: www.pentaxmedical.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari™ (L-Glutamine Oral Powder) in Sickle Cell Disease18.7.2018 21:45Pressemelding

VIEW E-MEDIA KIT – Emmaus Life Sciences, Inc. (Emmaus) announced today that the New England Journal of Medicine (NEJM) has published the results of its 48-week phase 3 clinical trial of Endari™ (L-glutamine oral powder) which supported the FDA approval in July 2017 to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. The article reports results that showed significantly fewer sickle cell crises in those receiving Endari compared to placebo by 25 percent; p=0.005 (median 3 vs. median 4) and significantly fewer hospitalizations by 33 percent; p=0.005 (median 2 vs. median 3). Additional findings showed lower cumulative days in hospital of 41 percent; p=0.02 (median 6.5 days vs. median 11 days) and a lower incidence of acute chest syndrome (ACS) by more than 60 percent; p=0.003 (13 of 152 patients [8.6%] had at least 1 ACS compared with 18 of 78 in the placebo group [23.1%]). The most common adverse reactions, occurring in great

Tigo Releases State-of-the-art Wireless Technology – Mesh – as the New Solar Communication Architecture for the TS4 Platform18.7.2018 19:41Pressemelding

Tigo®, pioneer of the smart modular Flex MLPE platform, today announced the release of its new Mesh communication architecture. This state-of-the-art wireless technology directly translates to customer benefits – including simplifying the solar design process and accelerating the commissioning steps. The complete Tigo solution uses a simple yet powerful data collection technology that covers the widest ranges of residential & commercial installations at the lowest cost. With Mesh and the recently announced Tigo Access Point (TAP), customers eliminate the need to address any roof obstruction or orientation constraint. To learn more about Mesh and TAP, register for Tigo’s free, online webinar “The Future of Solar is Wireless” on Wednesday July 25th, 2018 at 10am PDT. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180718005827/en/ Mesh is Tigo's proprietary software that allows each TS4 unit to act as a repeater, extending the

ViiV Healthcare Shares Data from Landmark 2-Drug Regimen Trials At AIDS 201818.7.2018 17:21Pressemelding

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting over 20 abstracts, including data from the landmark GEMINI 1 & 2 clinical trials, at the 22nd International AIDS Conference (AIDS 2018), 23-27 July 2018, in Amsterdam, The Netherlands. The data being presented this year has a strong focus on novel exploratory therapeutic options and innovative treatment strategies, as well as improving awareness and understanding of key issues that continue to affect the HIV community. John C Pottage, Jr, MD, Chief Scientific and Medical Officer, ViiV Healthcare, commented, “As we see advancements in the treatment options available to people living with HIV, our research efforts over the past few years have been focused on moving beyond viral load and addressing some of the unresolved issues that people living with HIV face, such as the potential long-term risks and toxicities that can be associated with li

Xilam: H1 2018 Revenue: +50%18.7.2018 16:00Pressemelding

Regulatory News: The Xilam Group (Paris:XIL) posted consolidated H1 2018 revenue of EUR 13,866 thousand, an increase of 50%. This increase represents an excellent performance, as it follows on the heels of growth of 54% in H1 2017. Revenue for the first part of this financial year breaks down as follows. In thousands of euros 30.06.2018 (1) 30.06.2017 Change New productions 8,465 4,571 +85% Catalogue 5,385 4,652 +16% Other 16 16 +0% Revenue and subsidies 13,866 9,239 +50% (1) Unaudited data. Remarkable success for new releases +85% Excellent H1 growth was driven by the two main businesses, New Productions and Catalogue. In New Productions, H1 deliveries generated record revenue of EUR 8,465 thousand, an 85% increase compared with H1 2017, and confirmed Xilam’s position as a major European animation company. Catalogue revenue was up 16% compared with H1 2017, thanks again to traditional TV channels and digital platforms, in both France and abroad. A fast-paced delivery schedule Thanks t

Department for International Trade: Life Sciences at the Heart of UK Economy18.7.2018 12:38Pressemelding

The Government will today (Wednesday 18 July) host the second in a series of roundtables with stakeholders from key life science businesses, demonstrating the importance of the sector to the UK economy. The Chancellor, International Trade Secretary, Business Secretary and Health and Social Care Secretary will be amongst those that meet with senior representatives from leading UK and international life sciences companies as the UK positions itself as the global home of health innovation, welcoming overseas investment and seeking to boost exports in the process. Discussions at the roundtable will focus on how the future of the Life Sciences sector will be supported by the delivery of our modern Industrial Strategy, ensuring that the UK is ‘open for business’ with a positive business environment, our ambitions for a comprehensive agreement with the EU on our future relationship and the development and implementation of our independent trade policy. To date, the government has engaged sign

Universal Laser Systems Expands Its Materials Database with 3M, Victrex and Dexmet Materials18.7.2018 12:05Pressemelding

Universal Laser Systems (ULS) announces the addition of 3M™, Victrex® and Dexmet materials to its materials database, the most extensive repository of laser material processing parameters for materials in the range of 10 watts to 500 watts. The 3M, Victrex and Dexmet materials new to the ULS materials database were specifically added for laser processing with the ULTRA and XLS platforms, suited for high accuracy and precision laser cutting, laser ablation and laser surface modification. The materials include: 3M™ Extreme Sealing Tape 4412N 3M™ Thermally Conductive Silicone Interface Pad 5516 Victrex® APTIV® PEEK Film Dexmet PolyGrid® 8PTFE10-125ST Expanded PTFE Dexmet MicroGrid® AL 25 Expanded Aluminum Laser processing notes, describing the results of the laser-material interaction for these materials, are also available in the Materials Library on the ULS website to help potential customers explore the advantages of deploying laser technology within their manufacturing, research and d